Navigation Links
Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
Date:12/15/2009

NEW YORK, Dec. 15 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

http://www.reportlinker.com/p0168102/The-Future-of-HIV-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html

Summary

The author has released its latest research "The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis." The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global HIV therapeutics market. The report analyzes the markets for HIV therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The scope of this report includes:

  • Annualized market data for the HIV therapeutics market from 2000 to 2008, forecast forward to 2015
  • Analysis of the HIV therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
  • Market characterization of the HIV therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns
  • Key drivers and barriers that have a significant impact on the market
  • Coverage of pipeline molecules in various phases of drug development
  • Competitive benchmarking of leading companies. The key companies studied in this report are Gilead Sciences Inc, GlaxoSmithKline, Bristol-Myers Squibb, Abbott Laboratories, Merck & Co and Pfizer Inc
  • Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global HIV therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Align product portfolio to the markets with high growth potential
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
  • Develop key strategic initiatives by understanding key focus areas of leading companies
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Global HIV Therapeutics Market: Introduction

2.1 GBI Research Report Guidance

3 Global HIV Therapeutics Market: Overview

3.1 Disease Overview

3.2 Market Overview

4 Global HIV Therapeutics Market: Market Characterization

4.1 Market Forecasts

4.2 Branded Versus Generics

4.3 Average Cost of Therapy

4.4 Volume

4.5 Usage Patterns

4.5.1 Diseased Population

4.5.2 Treatment Seeking Population

4.5.3 Diagnosis Population

4.5.4 Prescription Population

4.5.5 Usage Patterns

4.5.6 Geographical Distribution

4.6 HIV Therapeutics Market: Drivers and Restraints

4.7 Market Drivers

4.7.1 Increase in Awareness Levels of Disease Progression will Lead to Increase in Treatment Seeking and Diagnosed Population

4.7.2 New Product Launches with Better Efficacy will Drive the Market By Increasing Uptake

4.7.3 Increase in Drug Prices will Be a Key Driver for the Market by Driving Growth in the Next Few Years and Lowering Impact of Generics

4.8 Market Restraints

4.8.1 Patent Expirations and the Subsequent Entry of Generics will Impact the Market Negatively as Some People will Move to Generic Versions

4.8.2 Social Stigma Associated with HIV Leads to Low Rate of Treatment Seeking Thus Impacting the Overall Customer Base

4.8.3 Rigorous and Complex Treatment Regimes for Most HIV Therapies Result in Poor Patient Compliance Leading to Reduction in Drug Volumes

4.9 Market Trend

4.9.1 Incidence and Prevalence Rates are Increasing at a Slow Rate

4.9.2 Many New Companies are Actively Pursuing Different Classes of Drugs in Their Pipeline

4.9.3 Although DTC Advertising is Aimed at Increasing Awareness, it is Attracting Criticism for Incorrect Depiction of Therapeutic Benefits of Treatment Options

4.9.4 Current Reimbursement Scenario is Positive for HIV as Countries Reimburse Almost All of the Costs Associated with HIV Drugs

4.9.5 Regulatory Scenario for HIV Drugs is Positive and Many Countries Facilitate Quicker Review for HIV Drug Applications

5 Global HIV Therapeutics Market: The US Market

5.1 Market Forecasts

5.2 Average cost of Therapy

5.3 Volume

5.4 Usage Patterns

5.4.1 Diseased Population

5.4.2 Treatment Seeking Population

5.4.3 Diagnosis Population

5.4.4 Prescription Population

5.4.5 Usage Patterns

6 Global HIV Therapeutics Market: Europe Market

6.1 Market Forecasts

6.2 Average Cost of Therapy

6.3 Volume

6.4 Usage patterns

6.4.1 Diseased Population

6.4.2 Treatment Seeking Population

6.4.3 Diagnosis Population

6.4.4 Prescription Population

6.4.5 Usage Patterns

7 Global HIV Therapeutics Market: Japan Market

7.1 Market Forecasts

7.2 Average Cost of Therapy

7.3 Volume

7.4 Usage Patterns

7.4.1 Diseased Population

7.4.2 Treatment Seeking Population

7.4.3 Diagnosis Population

7.4.4 Prescription Population

7.4.5 Usage Patterns

8 Global HIV Therapeutics Market: Unmet Need

8.1 Different Classes of Drugs

8.1.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)

8.1.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

8.1.3 Protease Inhibitors

8.1.4 Viral Fusion (or Entry) Inhibitors

8.1.5 HIV Integrase Strand Transfer Inhibitors

8.1.6 Multi-class Combination Products

8.2 Unmet Need Analysis

8.2.1 HIV Drugs are Low in Efficacy as None of the Drugs Provide a Cure for the Disease However Newer Multi Class Combination Drugs Can Achieve Undetectable Level of HIV

8.2.2 When Compared to the Adverse Symptoms of HIV Infection Progression, the HIV Medications are Relatively Safe and Have Serious Side Effects Rarely

8.2.3 Average Cost of HIV Therapy is High, Leading to a Need for a More Cost Effective Treatment Option

8.3 Pipeline Analysis

8.3.1 Phase I

8.3.2 Phase II

8.3.3 Phase III

9 Global HIV Therapeutics Market: Competitive Landscape

9.1 Evolving Competitive Landscape

9.2 Market Share Analysis

9.2.1 Atripla, Truvada and Isentress are the HIV brands that will Drive the Market and Competition

9.3 Key Product Analysis

9.3.1 Truvada

9.3.2 Atripla

9.3.3 Viread

9.3.4 Isentress

9.3.5 Trizivir

9.3.6 Kaletra

9.3.7 Reyataz

9.3.8 Combivir

9.3.9 Epzicom/Kivexa

9.3.10 Sustiva Franchise

9.4 Competitive Profiling

9.4.1 Gilead

9.4.2 GlaxoSmithKline (GSK)

9.4.3 Bristol-Myers Squibb (BMS)

9.4.4 Abbott Laboratories

9.4.5 Merck

9.4.6 Pfizer

10 Global HIV Therapeutics Market: Strategic Consolidations

10.1 Overview

10.1.1 Total Deals by Type and Geography

10.2 Mergers and Acquisitions

10.3 Licensing Agreements

10.3.1 Preclinical

10.3.2 Phase II

10.3.3 Phase III

10.3.4 Approved

11 Global HIV Therapeutics Market: Conclusion

12 Global HIV Therapeutics Market: Appendix

12.1 Market Definitions

12.2 Abbreviations

12.3 Research Methodology

12.3.1 Coverage

12.3.2 Secondary Research

12.3.3 Primary Research

12.3.4 Forecasts

12.3.5 Expert Panel Validation

12.4 Contact Us

12.5 Disclaimer

12.6 Sources

1.1 List of Tables

Table 1: HIV Therapeutics Market, Global, Revenue ($m), 2000-2008

Table 2: HIV Market, Global, Revenue ($m), 2008-2015

Table 3: HIV Therapeutics Market, Global, Revenue Segmentation ($m), 2000-2008

Table 4: HIV Therapeutics Market, Global, Revenue Segmentation ($m), 2008-2015

Table 5: HIV Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2008

Table 6: HIV Therapeutics Market, Global, Average Cost of Therapy ($), 2008-2015

Table 7: HIV Therapeutics Market, Global, Volume (million), 2000-2008

Table 8: HIV Therapeutics Market, Global, Volume (million), 2008-2015

Table 9: HIV Therapeutics Market, Global, Diseased Population, 2000-2008

Table 10: HIV Therapeutics Market, Global, Diseased Population, 2008-2015

Table 11: HIV Therapeutics Market, Global, Treatment Seeking Population, 2000-2008

Table 12: HIV Therapeutics Market, Global, Treatment Seeking Population, 2008-2015

Table 13: HIV Therapeutics Market, Global, Diagnosis Population, 2000-2008

Table 14: HIV Therapeutics Market, Global, Diagnosis Population, 2008-2015

Table 15: HIV Therapeutics Market, Global, Prescription Population, 2000-2008

Table 16: HIV Therapeutics Market, Global, Prescription Population, 2008-2015

Table 17: HIV Therapeutics Market, Global, Usage Patterns, 2000-2008

Table 18: HIV Therapeutics Market, Global, Usage Patterns, 2008-2015

Table 19: HIV Therapeutics Market, Global, Market Drivers, 2008

Table 20: HIV Therapeutics Market, Global, Market Restraints, 2008

Table 21: HIV Therapeutics Market, Global, Key Drug Going Off Patent, 2008-15

Table 22: HIV Therapeutics Market, US, Revenues ($m), 2000-2008

Table 23: HIV Therapeutics Market, US, Revenue ($m), 2008-2015

Table 24: HIV Therapeutics Market, US, Average Cost of Therapy ($), 2000-2008

Table 25: HIV Therapeutics Market, US, Average Cost of Therapy ($), 2008-2015

Table 26: HIV Therapeutics Market, US, Volume (million), 2000-2008

Table 27: HIV Therapeutics Market, US, Volume (million), 2008-2015

Table 28: HIV Therapeutics Market, US, Diseased Population, 2000-2008

Table 29: HIV Therapeutics Market, US, Diseased Population, 2008-2015

Table 30: HIV Therapeutics Market, US, Treatment Seeking Population, 2000-2008

Table 31: HIV Therapeutics Market, US, Treatment Seeking Population, 2008-2015

Table 32: HIV Therapeutics Market, US, Diagnosis Population, 2000-2008

Table 33: HIV Therapeutics Market, US, Diagnosis Population, 2008-2015

Table 34: HIV Therapeutics Market, US, Prescription Population, 2000-2008

Table 35: HIV Therapeutics Market, US, Prescription Population, 2008-2015

Table 36: HIV Therapeutics Market, US, Usage Patterns, 2000-2008

Table 37: HIV Therapeutics Market, US, Usage Patterns, 2008-2015

Table 38: HIV Therapeutics Market, Europe, Revenues ($m), 2000-2008

Table 39: HIV Therapeutics Market, Europe, Revenue ($m), 2008-2015

Table 40: HIV Therapeutics Market, Europe, Average Cost of Treatment, 2000-2008

Table 41: HIV Therapeutics Market, Europe, Average Cost of Treatment, 2008-2015

Table 42: HIV Therapeutics Market, Europe, Volume (million), 2000-2008

Table 43: HIV Therapeutics Market, Europe, Volume (million), 2008-2015

Table 44: HIV Therapeutics Market, Europe, Diseased Population, 2000-2008

Table 45: HIV Therapeutics Market, Europe, Diseased Population, 2008-2015

Table 46: HIV Therapeutics Market, Europe, Treatment Seeking Population, 2000-2008

Table 47: HIV Therapeutics Market, Europe, Treatment Seeking Population, 2008-2015

Table 48: HIV Therapeutics Market, Europe, Diagnosis Population, 2000-2008

Table 49: HIV Therapeutics Market, Europe, Diagnosis Population, 2008-2015

Table 50: HIV Therapeutics Market, Europe, Prescription Population, 2000-2008

Table 51: HIV Therapeutics Market, Europe, Prescription Population, 2008-2015

Table 52: HIV Therapeutics Market, Europe, Usage Patterns, 2000-2008

Table 53: HIV Therapeutics Market, Europe, Usage Patterns, 2008-2015

Table 54: HIV Therapeutics Market, Japan, Revenue ($m), 2000-2008

Table 55: HIV Therapeutics Market, Japan, Revenue ($m), 2008-2015

Table 56: HIV Therapeutics Market, Japan, Average Cost of Therapy ($), 2000-2008

Table 57: HIV Therapeutics Market, Japan, Average Cost of Therapy ($), 2008-2015

Table 58: HIV Therapeutics Market, Japan, Volume (million), 2000-2008

Table 59: HIV Therapeutics Market, Japan, Volume (million), 2008-2015

Table 60: HIV Therapeutics Market, Japan, Diseased Population, 2000-2008

Table 61: HIV Therapeutics Market, Japan, Diseased Population, 2008-2015

Table 62: HIV Therapeutics Market, Japan, Treatment Seeking Population, 2000-2008

Table 63: HIV Therapeutics Market, Japan, Treatment Seeking Population, 2008-2015

Table 64: HIV Therapeutics Market, Japan, Diagnosis Population, 2000-2008

Table 65: HIV Therapeutics Market, Japan, Diagnosis Population, 2008-2015

Table 66: HIV Therapeutics Market, Japan, Prescription Population, 2000-2008

Table 67: HIV Therapeutics Market, Japan, Prescription Population, 2008-2015

Table 68: HIV Therapeutics Market, Japan, Usage Patterns, 2000-2008

Table 69: HIV Therapeutics Market, Japan, Usage Patterns, 2008-2015

Table 70: HIV Market, Global, Different Classes of Drugs

Table 71: HIV Therapeutics Market, Global, Pipeline Analysis, Phase I, 2008

Table 72: HIV Therapeutics Market, Global, Pipeline Analysis, Phase II, 2008

Table 73: HIV Therapeutics Market, Global, Pipeline Analysis, Phase III, 2008

Table 74: HIV Therapeutics Market, Global, Major Drugs and Manufacturers, 2008

Table 75: HIV Therapeutics Market, Global, Benchmarking Analysis for Top Three Companies, 2008

Table 76: HIV Therapeutics Market, Global, Licensing Agreements for Drugs in the Preclinical Stage, 2008

Table 77: HIV Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II, 2008

Table 78: HIV Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III, 2008

Table 79: HIV Therapeutics Market, Global, Licensing Agreements for Approved Drugs, 2008

1.2 List of Figures

Figure 1: HIV Therapeutics Market, Global, Market Overview, 2008

Figure 2: HIV Therapeutics Market, Global, Revenue ($m), 2000-2015

Figure 3: HIV Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015

Figure 4: HIV Therapeutics Market, Global, Volume (million), 2000-2015

Figure 5: HIV Therapeutics Market, Global, Diseased Population, 2000-2015

Figure 6: HIV Therapeutics Market, Global, Treatment Seeking Population, 2000-2015

Figure 7: HIV Therapeutics Market, Global, Diagnosis Population, 2000-2015

Figure 8: HIV Therapeutics Market, Global, Prescription Population, 2000-2015

Figure 9: HIV Therapeutics Market, Global, Usage Patterns, 2000-2015

Figure 10: HIV Therapeutics Market, Global, Geographical Distribution of Revenues ($m), 2000-2015

Figure 11: HIV Therapeutics Market, Global, Geographical Outlook, 2008

Figure 12: HIV Therapeutics Market, Global, Market Indicators, 2008

Figure 13: HIV Therapeutics Market, Global, Key Market Events, 2008-2015

Figure 14: HIV Therapeutics Market, US, Revenue ($m), 2000-2015

Figure 15: HIV Therapeutics Market, US, Average Cost of Therapy ($), 2000-2015

Figure 16: HIV Therapeutics Market, US, Volume (million), 2000-2015

Figure 17: HIV Therapeutics Market, US, Diseased Population, 2000-2015

Figure 18: HIV Therapeutics Market, US, Treatment Seeking Population, 2000-2015

Figure 19: HIV Therapeutics Market, US, Diagnosis Population, 2000-2015

Figure 20: HIV Therapeutics Market, US, Prescription Population, 2000-2015

Figure 21: HIV Therapeutics Market, US, Usage Patterns, 2000-2015

Figure 22: HIV Therapeutics Market, Europe, Revenue ($m), 2000-2015

Figure 23: HIV Therapeutics Market, Europe, Average Cost of Treatment ($), 2000-2015

Figure 24: HIV Therapeutics Market, Europe, Volume (million), 2000-2015

Figure 25: HIV Therapeutics Market, Europe, Diseased Population, 2000-2015

Figure 26: HIV Therapeutics Market, Europe, Treatment Seeking Population, 2000-2015

Figure 27: HIV Therapeutics Market, Europe, Diagnosis Population, 2000-2015

Figure 28: HIV Therapeutics Market, Europe, Prescription Population, 2000-2015

Figure 29: HIV Therapeutics Market, Europe, Usage Patterns, 2000-2015

Figure 30: HIV Therapeutics Market, Japan, Revenue ($m), 2000-2015

Figure 31: HIV Therapeutics Market, Japan, Average Cost of Therapy ($), 2000-2015

Figure 32: HIV Therapeutics Market, Japan, Volume (million), 2000-2015

Figure 33: HIV Therapeutics Market, Japan, Diseased Population, 2000-2015

Figure 34: HIV Therapeutics Market, Japan, Treatment Seeking Population, 2000-2015

Figure 35: HIV Therapeutics Market, Japan, Diagnosis Population, 2000-2015

Figure 36: HIV Therapeutics Market, Japan, Prescription Population, 2000-2015

Figure 37: HIV Therapeutics Market, Japan, Usage Patterns, 2000-2015

Figure 38: HIV Therapeutics Market, Global, Analysis of Unmet Needs for Major Drug Class, 2008

Figure 39: HIV Therapeutics Market, Global, Pipeline by Phase and Class, 2008

Figure 40: HIV Therapeutics Market, Global, Competitive Analysis of Major Manufacturers with Respect to Revenues, 2006-08

Figure 41: HIV Therapeutics Market, Global, Competitive Analysis of Top 4 Manufacturers, 2006-08

Figure 42: HIV Therapeutics Market, Global, Market Share of Top Manufacturers, 2008

Figure 43: HIV Therapeutics Market, Global, Benchmark of Top 10 Brands - 2008

Figure 44: HIV Therapeutics Market, Gilead, HIV Revenue as Percentage of Total Revenue, 2009

Figure 45: HIV Therapeutics Market, GSK, HIV Revenue as Percentage of Total Revenue, 2009

Figure 46: HIV Therapeutics Market, BMS, HIV Revenue as Percentage of Total Revenue, 2009

Figure 47: HIV Therapeutics Market, Abbott, HIV Revenue as Percentage of Total Revenue, 2009

Figure 48: HIV Therapeutics Market, Merck, HIV Revenue as Percentage of Total Revenue, 2009

Figure 49: HIV Therapeutics Market, Global, Deals by Geography and Type, 2008

Figure 50: HIV Therapeutics Market, Global, M&A Deals, 2008

Figure 51: HIV Therapeutics Market, Global, Major Licensing Agreements By Phase, 2008-09

Figure 52: GBI Research Methodology

Figure 53: GBI Research Market Forecasting Model

Companies mentioned

GlaxoSmithKline (GSK)

Bristol-Myers Squibb (BMS)

Abbott Laboratories

Pfizer

To order this report: Pharmaceutical Industry: The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

More Market Research Report


    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Site Profile: --> ... The Speech Recognition People, announced their latest primary healthcare case study ... reduce turnaround times and to save the practice money. ... 2013 Challenge: --> ,- Wirral CCG ,- ... Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
(Date:2/4/2016)...  The Senior Care Pharmacy Coalition (SCPC) today ... Jason Chaffetz (R-UT) and Ranking Member ... , "Developments in the Prescription Drug Market," to ... about abusive pharmacy benefit manager (PBM) pricing practices. ... Member Elijah Cummings (D-MD) are diligent, serious lawmakers ...
(Date:2/4/2016)... , Feb. 4, 2016  Montoya Love is ... in the field of Pharmaceuticals. Montoya is the Regulatory ... Manufacturing and ... Becton Dickinson provides healthcare institutions, clinical laboratories ... throughout fifty countries across the globe. ...
Breaking Medicine Technology:
(Date:2/8/2016)... CA (PRWEB) , ... February 08, 2016 , ... The ... held annually in this country. The AutismOne 2016 Conference, which is being held May ... they often won’t hear elsewhere about helpful interventions and causes of chronic illness in ...
(Date:2/7/2016)... Scottsdale, AZ (PRWEB) , ... February 07, 2016 ... ... & Neck and Facial Plastics, has added Kybella® to his medical and surgical ... is a newly approved FDA injectable medication used as a non-surgical alternative for ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research ... treatment helps to reduce the frequency and level of relapse. , ... Healthy Identity and Purpose,” will explore the critical tasks of the recovery phase ...
(Date:2/5/2016)... ... 2016 , ... Successful recruitment and retention efforts, new collaborations ... have all marked the last 12 months at Roswell Park Cancer Institute (RPCI). ... oldest cancer center, Candace S. Johnson, PhD, outlined the many accomplishments of her ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe A. ... a joint enrollment and degree completion agreement. The agreement, which begins with ... at FHU|Dickson. , The agreement allows students to be jointly admitted to ...
Breaking Medicine News(10 mins):